Metastatic pancreatic cancer has resisted nearly every advance in oncology of the past two decades. A phase 3 trial reported this year moved the number that matters.
Among 500 patients with previously treated metastatic pancreatic cancer, daraxonrasib extended median overall survival to 13.2 months compared with 6.7 months on standard chemotherapy. The results drew a standing ovation at the American Society of Clinical Oncology annual meeting and were published simultaneously in the New England Journal of Medicine.
For families facing this diagnosis, the practical question is not whether the science is impressive. It is whether the drug can be obtained, and the answer is complicated: daraxonrasib is not approved, but a pathway exists.
Two things worth setting down before anything else. Median survival of just over a year is a meaningful gain against a cancer where roughly 97% of people diagnosed with metastatic disease between 2015 and 2021 died within five years. It is not a cure, and nobody involved is describing it as one.
Why KRAS Was Considered Undruggable
More than 90% of pancreatic tumors are driven by mutations in the KRAS gene. The protein it codes for works like a switch controlling cell growth. When mutated, the switch jams in the on position and instructs cells to multiply without stopping.
Most targeted cancer drugs work by fitting into a pocket on a protein's surface, the way a key fits a lock. KRAS has an unusually smooth surface with no adequate pocket, which is why drug developers spent decades failing to bind it.
Daraxonrasib takes an indirect route. Rather than binding KRAS directly, it attaches to cyclophilin A, a molecule inside cells that helps fold proteins into their final shapes. That combined complex then binds the active form of the KRAS protein and shuts down its growth signal.
The design choice to target the active rather than inactive conformation is the conceptual shift that made the approach work.
Wungki Park, MD, a gastrointestinal medical oncologist at Memorial Sloan Kettering who led early-phase work on the drug, said it "could be a paradigm shift in how we treat pancreatic cancer."
What the Trial Showed and What It Did Not
The phase 3 trial enrolled patients with metastatic disease who had already received prior treatment. That is the specific population in which the survival benefit was demonstrated, and results should not be assumed to transfer to earlier-stage disease or first-line use until those trials report.
Side effects are common and not trivial. A prominent skin rash affected more than 86% of patients. Diarrhea, nausea, and inflammation of mucous membranes and around the fingernails were also reported.
Resistance is the open question. Daniel King, MD, PhD, a gastrointestinal medical oncologist at Northwell Health, offered the necessary counterweight, saying that "while this might be a breakthrough, it's hard to call it a miracle." He noted these are not cures and that determining why patients develop resistance to RAS-targeted treatment is the next challenge.
Two further trials are running. One is evaluating daraxonrasib alone and with chemotherapy in patients who have not had prior treatment. Another is testing it after surgery in patients with resectable disease.
How Patients Can Access It Right Now
This is the section most coverage omits, and it is the reason to read a story about an unapproved drug.
On May 1, 2026, the FDA issued a letter permitting an expanded access treatment protocol. Expanded access, sometimes called compassionate use, allows people who cannot enroll in a clinical trial to receive an investigational drug outside one.
The program is open to select patients with RAS-mutated pancreatic cancer who are not eligible for the ongoing trials. Access depends on individual cancer centers opening the protocol, which happens institution by institution rather than all at once.
The concrete step for a patient or family is to ask the treating oncologist two questions: whether the tumor has been tested for RAS mutations, and whether the center has opened either a daraxonrasib trial or the expanded access protocol. If the answer is no on the second, ask for a referral to a center that has.
Molecular tumor testing is the gateway. Without documented RAS mutation status, neither trial enrollment nor expanded access is possible.
The drug also holds FDA Breakthrough Therapy designation, granted in June 2025, and a Commissioner's National Priority Voucher intended to accelerate review. Full approval has not been granted, and no approval date has been announced.
What Families Should Weigh
Expanded access is not the same as approved treatment, and the distinction carries practical consequences. Insurance coverage for investigational drugs is inconsistent, travel to a participating center may be required, and eligibility criteria still apply.
Pancreatic cancer is the third-leading cause of cancer death in the United States and kills nearly 53,000 people a year. It rarely produces symptoms early and has no effective screening test, which is why most diagnoses come after the disease has spread.
Symptoms that warrant prompt evaluation include jaundice, unexplained weight loss, persistent upper abdominal or back pain, new-onset diabetes in an adult without other risk factors, and pale or greasy stools. None of these is specific to pancreatic cancer, and most people with them do not have it, but they should not be ignored.
Nobody should stop or change an existing treatment based on this reporting. Chemotherapy remains the standard of care until an alternative is approved, and switching outside a structured protocol is not an option a patient can arrange independently.
What Happens Next
The FDA review timeline has not been made public. Analysts and clinicians expect a decision could come later in 2026, though nothing is guaranteed.
Additional trial readouts in first-line and post-surgical settings will determine whether the drug moves earlier in treatment. Combination studies pairing RAS inhibitors with other agents to delay resistance are also expected.
The confirmed finding is that daraxonrasib nearly doubled median survival in previously treated metastatic pancreatic cancer. The most affected group is patients with RAS-mutated disease who have progressed on chemotherapy. The reasonable action is to confirm molecular testing and ask about trial or expanded access eligibility. The central uncertainty is how long the benefit lasts before resistance develops.
Frequently Asked Questions
What did the trial find? In 500 patients with previously treated metastatic pancreatic cancer, daraxonrasib extended median overall survival to 13.2 months compared with 6.7 months on chemotherapy.
Is the drug approved? No. It holds Breakthrough Therapy designation and an expanded access protocol is open, but the FDA has not granted full approval.
Who is eligible for expanded access? Select patients with RAS-mutated pancreatic cancer who cannot participate in the ongoing clinical trials, at centers that have opened the protocol.
What is the first step for a patient? Ask the oncologist whether the tumor has undergone molecular testing for RAS mutations, and whether the center has opened a trial or the expanded access program.
What are the side effects? Skin rash affected more than 86% of trial participants. Diarrhea, nausea and inflammation of mucous membranes and around the fingernails were also reported.
Is this a cure? No. Clinicians involved have been explicit that it is not. Resistance to RAS-targeted treatment is an unresolved challenge.
What symptoms should prompt an evaluation for pancreatic cancer? Jaundice, unexplained weight loss, persistent upper abdominal or back pain, new-onset adult diabetes without other risk factors, and pale or greasy stools warrant medical assessment.
